Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
INTROPIN vs FLOWTUSS
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Dopamine is a direct agonist at dopamine (D1 and D2) and beta-1 adrenergic receptors, and at higher doses, alpha-1 adrenergic receptors. It also causes release of norepinephrine from sympathetic nerve terminals.
FLOWTUSS (guaifenesin) is an expectorant that increases respiratory tract fluid secretions, reducing mucus viscosity and facilitating clearance.
Hemodynamic support in cardiogenic shock,Hypotension not due to hypovolemia,Adjunct in cardiopulmonary resuscitation,Off-label: Bradycardia unresponsive to atropine
Relief of productive cough associated with respiratory tract infections,Chronic obstructive pulmonary disease (COPD) exacerbations,Cystic fibrosis (off-label)
2-20 mcg/kg/min continuous IV infusion, titrated to achieve desired hemodynamic response. Typical initial dose: 5 mcg/kg/min.
10 mg orally every 4-6 hours as needed for cough; maximum 60 mg/day.
Approximately 2 minutes. Short half-life allows rapid titration by intravenous infusion; effects cease within 5-10 minutes of discontinuation.
Terminal elimination half-life is 4–6 hours in adults with normal renal function; prolonged to 8–12 hours in moderate renal impairment (Cr Cl 30–50 m L/min).
Metabolized in the liver, kidney, and plasma by monoamine oxidase (MAO) and catechol-O-methyltransferase (COMT) to inactive metabolites.
Hepatic metabolism via oxidation and demethylation; primarily excreted renally as metabolites.
Primarily renal: 80% as unchanged drug and 20% as inactive metabolites (normetanephrine, homovanillic acid). Biliary/fecal excretion is negligible (<2%).
Renal elimination of unchanged drug accounts for 60–70%; hepatic metabolism (30–40%) with fecal excretion of metabolites via bile (20–25%) and urine (10–15%).
25%, primarily to albumin.
85–90% bound to albumin and alpha-1-acid glycoprotein.
0.2 L/kg (0.16-0.24 L/kg). Small Vd indicates limited extravascular distribution; compatible with rapid onset and offset.
1.5–2.0 L/kg; indicates extensive tissue distribution (e.g., lungs, liver).
Oral: less than 5% due to extensive first-pass metabolism (MAO and COMT). Intramuscular: variable but limited due to peripheral vasoconstriction; not recommended.
Oral: 75–85% (first-pass metabolism accounts for 15–25% loss).
No specific GFR-based dose adjustment required; monitor for renal perfusion adequacy and adjust based on clinical response.
e GFR 30-60 m L/min: 5 mg every 6 hours; e GFR <30 m L/min: 5 mg every 8 hours.
No specific Child-Pugh-based adjustment; use with caution in severe hepatic impairment due to altered metabolism.
Child-Pugh Class B: 5 mg every 6 hours; Child-Pugh Class C: 2.5 mg every 8 hours.
0.5-20 mcg/kg/min continuous IV infusion; typical initial dose 2-5 mcg/kg/min, titrated to effect.
Children 2-6 years: 2.5 mg orally every 6 hours; 6-12 years: 5 mg orally every 6 hours; >12 years: same as adult.
Start at lower end of dosing range (2-5 mcg/kg/min) due to increased sensitivity and comorbid conditions; titrate cautiously.
Initial dose 5 mg every 6 hours; increase cautiously due to increased risk of dizziness and sedation.
None
None.
Can cause ectopic heartbeats, tachycardia, angina, palpitations, vasoconstriction, and hypertension,May increase myocardial oxygen demand,Risk of tissue necrosis with extravasation,Use with caution in patients with occlusive vascular disease,Hypovolemia should be corrected before administration
Avoid use with persistent or chronic cough (e.g., smoking, asthma, COPD) unless directed by a physician. Use caution in patients with renal impairment.
Pheochromocytoma,Uncorrected tachyarrhythmias,Hypersensitivity to sulfites (if formulation contains sulfites),Ventricular fibrillation
Hypersensitivity to guaifenesin or any component; concurrent use with other expectorants.
No significant food interactions. However, patients on INTROPIN may have underlying conditions requiring dietary modifications (e.g., low sodium for hypertension). Avoid tyramine-rich foods if also taking MAOIs, though not a direct interaction with dopamine itself.
No specific food interactions. Alcohol may increase CNS depressant effects (dizziness, sedation).
Pregnancy Category C. In first trimester, animal studies show fetal abnormalities (e.g., skeletal and visceral malformations) at high doses. Second and third trimesters: risk of reduced uteroplacental blood flow and fetal hypoxia due to vasoconstriction; may induce preterm labor.
FLOWTUSS contains guaifenesin and dextromethorphan. Guaifenesin is FDA pregnancy category C; animal studies show fetal abnormalities at high doses, but human data insufficient. Dextromethorphan is category C; limited human studies show no clear teratogenic risk, but high doses may cause fetal toxicity. Avoid in first trimester; use only if benefit outweighs risk in second and third trimesters.
Excreted in breast milk in low concentrations; M/P ratio unknown. Potential for cardiovascular effects in infant; weigh benefits against risks.
Guaifenesin and dextromethorphan are excreted in breast milk in low amounts. M/P ratio not established for either. Use with caution; monitor infant for sedation or respiratory depression.
No specific dose adjustment required; start at low doses and titrate to effect due to altered hemodynamics and increased plasma volume in pregnancy.
No standard dose adjustment recommended during pregnancy. Use lowest effective dose for shortest duration. Consider pharmacokinetic changes in pregnancy (increased clearance of dextromethorphan may require higher doses for efficacy, but safety limits apply).
INTROPIN (dopamine) is a catecholamine with dose-dependent effects: low dose (1-5 mcg/kg/min) stimulates D1 receptors causing renal vasodilation; intermediate dose (5-10 mcg/kg/min) activates β1 receptors increasing cardiac contractility and heart rate; high dose (>10 mcg/kg/min) stimulates α1 receptors leading to vasoconstriction. Monitor for extravasation as it can cause tissue necrosis; treat with phentolamine infiltration. Taper infusion gradually to avoid hypotension. Contraindicated in pheochromocytoma and uncorrected tachyarrhythmias.
FLOWTUSS (guaifenesin) is an expectorant that increases respiratory tract fluid secretion, reducing mucus viscosity. Onset of action is 30-60 minutes. Maximum effect requires adequate hydration (8-10 glasses of water daily). Not recommended for chronic cough due to smoking, asthma, or emphysema. Avoid use in patients with persistent cough lasting >1 week or accompanied by fever, rash, or headache. May cause dizziness; caution when driving.
This medication is given intravenously and requires continuous monitoring in a hospital setting.,Report any pain, burning, or swelling at the IV site immediately.,You may experience increased heart rate, chest pain, or shortness of breath; notify staff promptly.,Inform your healthcare provider if you have a history of irregular heartbeat, high blood pressure, or thyroid disease.,Do not stop or change the infusion rate; it is controlled by medical staff.
Drink plenty of water to help loosen mucus.,Do not take more than 6 doses in 24 hours.,Discontinue and consult doctor if cough persists >7 days or if fever, rash, or headache develop.,Avoid alcohol; may increase dizziness.,Do not use for chronic cough from smoking or asthma without medical advice.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about INTROPIN vs FLOWTUSS, answered by our medical review team.
INTROPIN is a Catecholamine Vasopressor that works by Dopamine is a direct agonist at dopamine (D1 and D2) and beta-1 adrenergic receptors, and at higher doses, alpha-1 adrenergic receptors. It also causes release of norepinephrine from sympathetic nerve terminals.. FLOWTUSS is a Expectorant that works by FLOWTUSS (guaifenesin) is an expectorant that increases respiratory tract fluid secretions, reducing mucus viscosity and facilitating clearance.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between INTROPIN and FLOWTUSS depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of INTROPIN is: 2-20 mcg/kg/min continuous IV infusion, titrated to achieve desired hemodynamic response. Typical initial dose: 5 mcg/kg/min.. The standard adult dose of FLOWTUSS is: 10 mg orally every 4-6 hours as needed for cough; maximum 60 mg/day.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between INTROPIN and FLOWTUSS in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. INTROPIN is classified as Category C. Pregnancy Category C. In first trimester, animal studies show fetal abnormalities (e.g., skeletal and visceral malformations) at high doses. Second and third trimesters: risk of re. FLOWTUSS is classified as Category C. FLOWTUSS contains guaifenesin and dextromethorphan. Guaifenesin is FDA pregnancy category C; animal studies show fetal abnormalities at high doses, but human data insufficient. Dex. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.